Day: September 27, 2016

Amgen Multiple Myeloma Drug Fails to Surpass Competition in Trial

Shares of Amgen fell slightly—by 1.5 percent, to $170.90—this week on the report that its multiple myeloma drug—carfilzomib, under the brand name Kyprolis–did not outperform the competition in a head-to-head, late-stage study regarding efficacy on previously untreated patients. The United States Food and Drug Administration had already approved Kyprolis for multiple myeloma patients who had…

Close
Menu